OCC 2.63% 39.0¢ orthocell limited

Media thread, page-415

  1. 7,527 Posts.
    lightbulb Created with Sketch. 6785
    Thanks for posting. That was a far less conservative speech and presentation by PA. I like it.

    Calling $50 million yearly Striate wholesale revenue alone as Henry Schein rotates use from the old product to Striate. That's a rather large and forthright guidance call and very much above most expectations I am sure.

    Remplir US mkt entry I was calling/hoping late 2024 with 2Q CY24 registration study results, but will take 1Q CY25.

    $250 million yearly wholesale revenue call from Remplir at 20% of market another big guidance call. I like it. I'd settle for $100 million a year and $50 millioin from Striate.

    I've been banging on for over a year now has this company is easily funded to Remplir entry (which the company affirms in its slides) and has indeed already shown outside of R&D to get ATI and Remplir to market, is already operationally cash flow positive. Market/investors missing a beat here....
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
39.0¢
Change
0.010(2.63%)
Mkt cap ! $81.63M
Open High Low Value Volume
37.5¢ 39.0¢ 37.5¢ $49.66K 129.0K

Buyers (Bids)

No. Vol. Price($)
3 20305 37.5¢
 

Sellers (Offers)

Price($) Vol. No.
39.0¢ 77938 2
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.